Format

Send to

Choose Destination
Exp Clin Psychopharmacol. 2005 Nov;13(4):282-92.

Combined effects of venlafaxine, nicotine replacement, and brief counseling on smoking cessation.

Author information

1
Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston, 77230, USA. pcinciri@mdanderson.org

Abstract

In this study, 147 smokers were randomly assigned to receive either venlafaxine or placebo in conjunction with behavioral counseling (9 weekly sessions) and transdermal nicotine replacement therapy (22 mg/day). Patients began medication 2 weeks before quitting and continued for 18 weeks after quitting, with the daily dose titrated from 150 to 225 mg. in response to symptoms of negative affect and relapse. The results showed no main effect of treatment on abstinence. Post hoc analysis revealed that both at the end of treatment and at the 1-year follow-up smokers consuming less than a pack of cigarettes a day benefited from the addition of venlafaxine to the treatment regimen. Venlafaxine also reduced negative affect for all smokers for up to 6 weeks postcessation. The findings suggest that venlafaxine could have some role to play in the treatment of lighter smokers, in addition to the expected benefits of nicotine replacement therapy and behavioral counseling.

PMID:
16366758
DOI:
10.1037/1064-1297.13.4.282
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for American Psychological Association
Loading ...
Support Center